Patents Assigned to NOVARTIS FORSCHUNGSSTIFTUNG
  • Novel therapeutical tools and methods for treating blindness
    Publication number: 20160250282
    Abstract: The present inventions relates to the use of an isolated nucleic acid molecule comprising a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence complementary to said nucleotide sequence, for treating or ameliorating blindness. The light-gated ion channel or pump gene can be a halorhodopsin gene.
    Type: Application
    Filed: January 25, 2016
    Publication date: September 1, 2016
    Applicant: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Resear
    Inventor: Rita HABAR
  • Method of treatment of breast cancers over-expressing the SHP2 signature genes
    Patent number: 9181553
    Abstract: A method for treating breast cancer in a subject having a breast cancer over-expressing the “SHP2 signature” genes, as compared to normal breast tissue samples, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2).
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: November 10, 2015
    Assignee: NOVARTIS FORSCHUNGSSTIFTUNG ZWEIGNIEDERLASSUNG FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Mohamed Bentires-Alj, Nicola Aceto, Michael Stadler
  • INHIBITION OF INTERLEUKIN-8 AND/OR ITS RECEPTOR CXCR1 IN THE TREATMENT OF HER2/HER3-OVEREXPRESSING BREAST CANCER
    Publication number: 20150266961
    Abstract: The present invention relates to a method for treating breast cancer in a subject having a breast cancer characterized by activation of the HER2/HER3 heterodimer, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of interleukin 8 (IL8) and/or of its receptor chemokine (C-X-C motif) receptor 1 (CXCR1).
    Type: Application
    Filed: March 27, 2013
    Publication date: September 24, 2015
    Applicant: NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG, FRIDRICH MIESCHER INSTITUTE
    Inventors: Mohamed Bentires-Alj, Nicola Aceto
  • USE OF LIGHT SENSITIVE GENES
    Publication number: 20150246094
    Abstract: The invention relates to the use of a light-gated ion channel for the manufacture of a medicament for the treatment of blindness and a method for expressing said cell specific fashion, e.g. in ON-bipolar cells, ON-ganglion cells, or AII amacrine cells.
    Type: Application
    Filed: February 3, 2015
    Publication date: September 3, 2015
    Applicant: NOVARTIS FORSCHUNGSSTIFTUNG
    Inventors: Pamela Sarita LAGALI, Thomas Alexander MUENCH, Botond ROSKA
  • Use of protease nexin 1 inhibitors to reduce metastasis
    Patent number: 8933212
    Abstract: The present invention relates to a method of inhibiting metastasis comprising the administration of an inhibitor of protease nexin-1 (PN-1), characterized in that said inhibitor is administered at a therapeutical dosage that does not completely inhibit the expression and/or activity of PN-1.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: January 13, 2015
    Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
    Inventors: Bérengère Fayard, Denis Monard
  • Rod cell-specific promoter
    Publication number: 20140287510
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 200 bp having at least 70% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: November 7, 2012
    Publication date: September 25, 2014
    Applicant: NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG FRIEDRICH MIESCHER INSTITUTE
    Inventors: Sandra Siegert, Josephine Juettner, Botond Roska
  • CULTURE MEDIUM SUITABLE FOR THE CULTURE OF UNDIFFERENTIATED CELLS
    Publication number: 20140178894
    Abstract: The present application relates to a composition comprising the components listed in Table I in an amount that will lead to the respective concentration specified in Table I for each of said component when said composition is diluted with water into 1× medium, said composition being particularly suitable to generate a chemically-defined medium suitable for culturing cells, especially primary cells, maintaining their proliferation and differentiation potential.
    Type: Application
    Filed: April 20, 2011
    Publication date: June 26, 2014
    Applicant: NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG
    Inventors: Mohamed Bentires-Alj, Stephan Duss
  • PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11 (PTPN11) AND TRIPLE-NEGATIVE BREAST CANCER
    Publication number: 20140134184
    Abstract: The present invention relates to a method for treating breast cancer in a subject having a breast cancer of the triple-negative type, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2).
    Type: Application
    Filed: June 5, 2012
    Publication date: May 15, 2014
    Applicant: NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG
    Inventors: Mohamed Bentires-Alj, Nicola Aceto, Michael Stadler
  • USE OF LIGHT SENSITIVE GENES
    Publication number: 20140094506
    Abstract: The invention relates to the use of a light-gated ion channel for the manufacture of a medicament for the treatment of blindness and a method for expressing said cell specific fashion, e.g. in ON-bipolar cells, ON-ganglion cells, or AII amacrine cells.
    Type: Application
    Filed: December 9, 2013
    Publication date: April 3, 2014
    Applicant: NOVARTIS FORSCHUNGSSTIFTUNG
    Inventors: David BAYLA, Pamela LAGLALI, Thomas MUNCH, Botond ROSKA
  • Teneurin and cancer
    Patent number: 8642280
    Abstract: The present invention relates to a method for treating cancer, for instance brain tumors, in a subject by inhibiting a teneurin by administering to said subject a therapeutically effective amount of a modulator of said teneurin, for example a specific antibody or a siRNA. The present invention also encompasses methods of diagnosing cancer by measuring levels of teneurin.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: February 4, 2014
    Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
    Inventors: Ruth Chiquet-Ehrismann, Daniela Kenzelmann Bro{hacek over (z)}
  • Genetic vasectomy by overexpression of PRML-EGFP fusion protein in spermatids
    Patent number: 8633348
    Abstract: The present invention provides a genetically-modified non-human animal whose somatic and germ cells contain an exogenous gene encoding a recombinant fusion protein, wherein the presence, and expression, of said recombinant fusion protein renders said genetically-modified non-human animal sterile. Tools for generating such sterile genetically-modified non-human animal as well as methods of use thereof are also provided.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: January 21, 2014
    Assignees: Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute for Biomedical Research, Universität Zürich
    Inventors: Pawel Pelczar, Thorsten Buch, Antoine Peters
  • TREATING CANCER BY MODULATING MAMMALIAN STERILE 20-LIKE KINASE 3
    Publication number: 20130089538
    Abstract: The present invention relates to a method for modulating miRNA, said method being characterized in that a modulator of XRN1 is used. Also provided are uses of said method for therapeutical purposes, reagents therefore, as well as screening methods.
    Type: Application
    Filed: June 9, 2011
    Publication date: April 11, 2013
    Applicant: Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh
    Inventors: Hauke Hermann Karl Cornils, Brian Arthur Hemmings, Mario Reinhard Stegert
  • MODULATING XRN1
    Publication number: 20130034543
    Abstract: The present invention relates to a method for modulating miRNA, said method being characterized in that a modulator of XRN1 is used. Also provided are uses of said method for therapeutical purposes, reagents therefore, as well as screening methods.
    Type: Application
    Filed: April 18, 2011
    Publication date: February 7, 2013
    Applicant: Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Resear
    Inventors: Saibal Chatterjee, Helge Grosshans
  • Use of Light Sensitive Genes
    Publication number: 20130005795
    Abstract: The invention relates to the use of a light-gated ion channel for the manufacture of a medicament for the treatment of blindness and a method for expressing said cell specific fashion, e.g. in ON-bipolar cells, ON-ganglion cells, or AII amacrine cells.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 3, 2013
    Applicant: NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDER- LASSUNG FRIEDRICH MIESCHER INSTITUTE
    Inventors: David Bayla, Pamela Sarita Laglali, Thomas Alexander Muench, Botond Roska
  • RGMc modified transgenic animals
    Patent number: 8101816
    Abstract: The invention provides a new reproducible transgenic mouse model for the study of iron accumulation in the body. In particular, the invention concerns the study of iron overload in an RGMc knockout mouse model and its use in drug discovery and research.
    Type: Grant
    Filed: July 22, 2005
    Date of Patent: January 24, 2012
    Assignee: Novartis Forschungsstiftung, Zweigniederalassung Friedrich Miescher Institute for Biomedical Research
    Inventor: Silvia Arber
  • MODULATING XRN2
    Publication number: 20110300155
    Abstract: The present invention relates to a method for modulating miRNA, said method being characterized in that a modulator of XRN2 is used. Also provided are uses of said method for therapeutical purposes, reagents therefore, as well as screening methods.
    Type: Application
    Filed: December 3, 2009
    Publication date: December 8, 2011
    Applicant: NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG, F RIEDRICH MIESCHER INSTITUTE FOR BIOMWDICAL RESEAR
    Inventors: Saibal Chatterjee, Helge Grosshans
  • TREATING CANCER BY MODULATING MNK
    Publication number: 20110280886
    Abstract: The present invention relates to a method for treating cancer in a subject using a mTOR inhibitor in combination with a therapeutically effective amount of a modulator of a MNK.
    Type: Application
    Filed: November 11, 2009
    Publication date: November 17, 2011
    Applicants: UNIVERSITY HOSPITAL BASEL, NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG, F RIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEAR
    Inventors: Michal Grzmil, Brian Arthur Hemmings, Adrian Merlo, Pier Jr Morin
  • TREATING CANCER BY MODULATING RNA HELICASES
    Publication number: 20110262428
    Abstract: The present invention relates to a method for treating cancer in a subject by inhibiting DHX36, by administering to said subject a therapeutically effective amount of a modulator of DHX36.
    Type: Application
    Filed: September 22, 2009
    Publication date: October 27, 2011
    Applicant: NOVARTIS Forschungsstiftung Zweigniederlassung Fri -edrich Miescher Institute for Biomedical Researc
    Inventors: Mohamed Bentires-Alj, Yoshikuni Nagamine
  • NOVEL MITOCHONDRIAL DYE
    Publication number: 20110097731
    Abstract: The present invention relates to the use of single-barrel genetically encoded GFP-based calcium indicator as an intramitochondrial dye and to nucleic acid molecules coding for said indicators, as well as to methods using said indicators. Examples of single-barrel genetically encoded GFP-based calcium indicator is a GCaMP, Case16 and/or Case12. In a particular embodiment, the single-barrel genetically encoded GFP-based calcium indicator is GCaMP2 or Case16.
    Type: Application
    Filed: June 24, 2009
    Publication date: April 28, 2011
    Applicant: Novartis Forschungsstiftung, Zweigniederlassung Friedrich Mischer Institute for Biomedical Researc
    Inventors: Thomas Oertner, Tobias Rose
  • Purified PKB Ser 473 kinase and uses thereof
    Patent number: 7794995
    Abstract: This invention provides purified PKB Ser 473 kinase and methods of purifying it. The methods involve the use of several sequential steps, including subcellular fractionation to isolate a plasma membrane fraction and the use of gel filtration or chromatography that separates molecules according to their size or affinity.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: September 14, 2010
    Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
    Inventors: Jianhua Feng, Brian A Hemmings, Michelle M Hill